Patents Assigned to Nippon Zoki Pharmaceuticals Co., Ltd.
-
Publication number: 20240000853Abstract: A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.Type: ApplicationFiled: July 20, 2023Publication date: January 4, 2024Applicants: HYOGO COLLEGE OF MEDICINE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Tomohiro MATSUYAMA, Takayuki NAKAGOMI, Yu FUKUDA
-
Publication number: 20230330042Abstract: An oral preparation contains tramadol or a pharmaceutically acceptable salt thereof as an active ingredient and has a low incidence of side effects, such that the blood concentration of unchanged tramadol or an active metabolite thereof, for example, falls within a certain numerical range after administration, so that the incidence of side effects is low while the efficacy is excellent.Type: ApplicationFiled: September 22, 2021Publication date: October 19, 2023Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Tsuyoshi ADACHI, Kenji MITSUDA, Hideshi NAKANO
-
Publication number: 20230302040Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.Type: ApplicationFiled: May 4, 2023Publication date: September 28, 2023Applicants: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD., OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki TANAKA, Hideki YOSHIKAWA, Hideki MOCHIZUKI, Tsuyoshi MURASE, Tsutomu SASAKI, Kousuke BABA, Toru IWAHASHI, Mitsuru NAIKI
-
Patent number: 11679122Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.Type: GrantFiled: May 19, 2022Date of Patent: June 20, 2023Assignees: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Tanaka, Hideki Yoshikawa, Hideki Mochizuki, Tsuyoshi Murase, Tsutomu Sasaki, Kousuke Baba, Toru Iwahashi, Mitsuru Naiki
-
Publication number: 20230167409Abstract: A method of culturing a cell population containing cartilage-derived cells positive for expression of Tie2 (cartilage-derived Tie2-positive cells), the method including culturing a cell population containing cartilage-derived Tie2-positive cells in a culture medium containing at least one kind of Tie2 expression enhancer other than growth factors (e.g., an extract derived from a plant of the genus Cinnamomum). This culturing method is preferably performed in cultureware having a culture surface coated with a coating agent (e.g., a polylysine-containing agent).Type: ApplicationFiled: April 26, 2021Publication date: June 1, 2023Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Daisuke SAKAI, Yoshihiko NAKAMURA, Erika MATSUSHITA
-
Publication number: 20230066066Abstract: A medical sheet has a cell infiltration suppressing action, including a nonwoven fabric formed of fiber containing an aliphatic polyester, and having a porosity of 50 to 90%. The sheet is very useful because it has an excellent neuroprotective and/or nerve regeneration promoting action, which protects nerves by suppressing the infiltration of inflammatory cells such as macrophages and not giving stimulation that adversely affects nerves because body fluids pass therethrough, by winding around a nerve at a peripheral nerve injury site.Type: ApplicationFiled: January 14, 2021Publication date: March 2, 2023Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Takafumi KONISHI, Mitsuru NAIKI, Toshiko UJITA, Hitoshi YAMAMOTO
-
Patent number: 11529374Abstract: It is an object of the present invention to provide an extract from inflamed skins of rabbits inoculated with vaccinia virus wherein the quality is more stabilized, and a preparation containing the extract, etc. The use of the amount of N-acetylneuraminic acid contained in an extract from inflamed skins of rabbits inoculated with vaccinia virus and a preparation containing the extract as an index makes possible to warrant the quality of each manufacturing lot of the extract and the preparation in more stable manner. The extract from inflamed skins of rabbits inoculated with vaccinia virus and the preparation containing the extract which are manufactured as above, and in which the quality thereof becomes more stable, are warranted to maintain efficacy and safety in more strict manner, and thus extremely useful.Type: GrantFiled: December 6, 2018Date of Patent: December 20, 2022Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Yoshitaka Nakazawa, Yoji Shibayama, Ko Nakamura
-
Patent number: 11464762Abstract: A carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration. A carcinogenesis inhibitor containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.Type: GrantFiled: June 12, 2018Date of Patent: October 11, 2022Assignees: NATIONAL CANCER CENTER, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Michihiro Mutoh, Yurie Kurokawa, Gen Fujii, Shingo Miyamoto
-
Patent number: 11458102Abstract: A preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent dissolution properties, preferable hardness and high drug content uniformity and a manufacturing method thereof. Acetaminophen has a preset particle size and is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed, manufacturing efficiency can be elevated and the cost for manufacturing is also reduced. Thus, an acetaminophen preparation having improved administrability, for example, a reduced size and a manufacturing method thereof are highly useful.Type: GrantFiled: November 8, 2018Date of Patent: October 4, 2022Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Sakamoto, Kunio Komai, Kenji Sakakibara, Hirokazu Banba, Kiyoshi Fukuda
-
Patent number: 11433031Abstract: A method for manufacturing a preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent elution properties, preferable hardness and high drug content uniformity, and a premix drug substance of acetaminophen which has improved manufacturability. According to the method in which acetaminophen having a preset particle size is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed and manufacturing efficiency can be elevated. Thus, this method is highly useful for manufacturing an acetaminophen preparation having improved administrability, for example, a reduced size.Type: GrantFiled: April 5, 2021Date of Patent: September 6, 2022Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Sakamoto, Kunio Komai, Kenji Sakakibara, Hirokazu Banba, Kiyoshi Fukuda
-
Publication number: 20220273692Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.Type: ApplicationFiled: May 19, 2022Publication date: September 1, 2022Applicants: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki TANAKA, Hideki YOSHIKAWA, Hideki MOCHIZUKI, Tsuyoshi MURASE, Tsutomu SASAKI, Kousuke BABA, Toru IWAHASHI, Mitsuru NAIKI
-
Patent number: 11369626Abstract: A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.Type: GrantFiled: June 22, 2020Date of Patent: June 28, 2022Assignees: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Tanaka, Hideki Yoshikawa, Hideki Mochizuki, Tsuyoshi Murase, Tsutomu Sasaki, Kousuke Baba, Toru Iwahashi, Mitsuru Naiki
-
Patent number: 11324704Abstract: Provided is a sustained release sheet that includes a drug for treating nerve injury, wherein the sheet is applied to a nerve injury site, can maintain a high concentration of the drug over a long period, and promotes nerve regeneration without stimulating the nerves, even when the sheet is implanted in the periphery of the nerve injury site. Also provided is a production method for the sheet. This sustained drug release sheet for treating nerve injury is a sheet comprising a non-woven fabric that is formed from nanofibers each containing a drug such as vitamin B12 and a biocompatible polymer such as a biodegradable aliphatic polyester, and is implanted in the periphery of the nerve injury site to promote nerve regeneration.Type: GrantFiled: March 6, 2017Date of Patent: May 10, 2022Assignees: OSAKA UNIVERSITY, NATIONAL INSTITUTE FOR MATERIALS SCIENCE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Tanaka, Kiyoshi Okada, Hideki Yoshikawa, Koji Suzuki, Mitsuhiro Ebara
-
Publication number: 20220096561Abstract: An inhibiting or alleviating agent for inflammation in the brain comprising an extract from inflamed tissue inoculated with vaccinia virus as the active ingredient. In another aspect, the invention relates to a determination or evaluation method of an extract from inflamed tissue inoculated with vaccinia virus or an agent comprising the extract, characterized in that the inhibition of the expression of pro-inflammatory cytokines and/or NF-?B pathway related proteins induced by the promotion of expression of BDNF in cultivated glial cells is used as an indicator. In still another aspect, the invention also relates to a use of an extract from inflamed tissue inoculated with vaccinia virus in the production of the inhibiting or alleviating agent for inflammation in the brain.Type: ApplicationFiled: January 30, 2019Publication date: March 31, 2022Applicants: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Jun LIU, Wang LIAO, Wenli FANG, Shengnuo FAN, Yuqiu ZHENG
-
Publication number: 20220079995Abstract: An object of the present invention is to provide an agent for promoting expression of N-acetylgalactosaminyltransferase that contains an extract from inflamed tissues inoculated with vaccinia virus. The present invention demonstrated that the extract from inflamed tissues inoculated with vaccinia virus promotes the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells. Thus, the extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract is useful as an agent for promoting the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells.Type: ApplicationFiled: November 26, 2021Publication date: March 17, 2022Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Daisuke SAKAI, Tomoko NAKAI, Mitsuru NAIKI, Yoji SHIBAYAMA
-
Publication number: 20220056418Abstract: Preparing a cell population rich in cells having a given phenotype depending on their use (e.g., type II collagen-positive nucleus pulposus cells) from a cell population containing Tie2-positive stem/progenitor cells (e.g., nucleus pulposus stem/progenitor cells). The present invention provides culture methods wherein a cell population containing Tie2-positive stem/progenitor cells is cultured (1) while present in a non-digested tissue, (2) in a culture medium containing at least one kind of Tie2 expression enhancer other than growth factors, (3) using cultureware with a culture surface having undergone cell attachment-increasing treatment, or (4) while suppressing formation of spheroid colonies in a culture medium containing an extracellular matrix-degrading agent.Type: ApplicationFiled: March 25, 2020Publication date: February 24, 2022Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Daisuke SAKAI, Yoshihiko NAKAMURA, Erika MATSUSHITA
-
Patent number: 11235006Abstract: An inhibiting or alleviating agent for amyloid beta (A?)-induced damage in hippocampus including an extract from inflamed tissues inoculated with vaccinia virus. Also relates to the use of the extract from inflamed tissues inoculated with vaccinia virus in the preparation of an agent for inhibiting or alleviating A?-induced damage in hippocampus.Type: GrantFiled: March 6, 2017Date of Patent: February 1, 2022Assignees: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventor: Jun Liu
-
Patent number: 11207354Abstract: A Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like contain an extract from inflamed tissues inoculated with vaccinia virus. The extract from inflamed tissues inoculated with vaccinia virus promotes differentiation of Schwann cells and regeneration of a peripheral nerve. Therefore, a preparation containing the extract from inflamed tissues inoculated with vaccinia virus is useful as a Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like.Type: GrantFiled: September 22, 2017Date of Patent: December 28, 2021Assignees: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Tanaka, Tsuyoshi Murase, Hideki Yoshikawa, Hiroki Fujisawa
-
Patent number: 11129976Abstract: The object of the present invention is to provide a test method using a novel administration method of an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract. It has been demonstrated that by sustainedly administering an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract by using a continuous administration device according to the present invention, a comparable effect is exerted at a very low dose compared with conventional administration methods such as oral administration. Therefore, the present invention can provide a test method using animals requiring less burden on a researcher, a treatment of patient at a low dose, and the like.Type: GrantFiled: February 24, 2017Date of Patent: September 28, 2021Assignees: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Tanaka, Tsuyoshi Murase, Hideki Yoshikawa, Mitsuru Naiki, Tomonori Matsumoto
-
Publication number: 20210267900Abstract: The present invention relates to a pre-processing method for the purpose of formulating a drug substance having non-uniform particle sizes by a manufacturing method having excellent manufacture performance. According to the pre-processing method of the present invention, additives including at least a dispersant are blended in a drug substance having a specific particle size distribution and then the resultant mixture is deagglomerated/sized to disperse and make adhere the additives onto the surfaces of the particles of the drug substance, thereby yielding a powder having a specified particle size distribution. In this manner, a pharmaceutical preparation can be manufactured with excellent manufacture performance, manufacture efficiency, and manufacture cost by a direct compression method, a wet continuous granulation system or the like. Therefore, the pre-processing method is very useful.Type: ApplicationFiled: June 25, 2019Publication date: September 2, 2021Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi SAKAMOTO, Kunio KOMAI, Kiyoshi FUKUDA, Kensuke NAMBA, Kaori SHIMOAKA